Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

References

• Tenold M, Ravi P, Kumar M, et al. Current approaches to the treatment of advanced or metastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book. 2020;40:1–10.
   PubMedGoogle Scholar
• Yan M, Richard Gregg R, Mahmud A. Outcomes of multi-disciplinary management of metastatic renal cell carcinoma. Cureus. 2019;11(10):e5901.
   PubMed Web of Science ®Google Scholar
• Mennitto A, Verzoni E, Grassi P, et al. Multimodal treatment of advanced renal cancer in 2017. Expert Rev Clin Pharmacol. 2017;10(12):1395–1402.
   PubMed Web of Science ®Google Scholar
• Albiges L, Oudard S, Negrier S, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol. 2012;30(5):482–487.
   PubMed Web of Science ®Google Scholar
• Mennitto A, Verzoni E, Calareso G, et al. Treatment of advanced renal cell carcinoma: recent advances and current role of immunotherapy, surgery, and cryotherapy. Tumori. 2017;103(1):15–21.
   PubMed Web of Science ®Google Scholar
• Bex A. Integrating metastasectomy and stereotactic radiosurgery in the treatment of metastatic renal cell carcinoma. EJC Suppl. 2013;11(2):192–203.
   PubMedGoogle Scholar
• Omid S, Abufaraj M, Remzi M. Metastasectomy in patients with renal cell carcinoma: when and how? Curr Opin Urol. 2020;30(4):602–609.
   PubMed Web of Science ®Google Scholar
• Apollonio G, Raimondi A, Verzoni E, et al. The role of metastasectomy in advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2019;19(7):603–611.
   PubMed Web of Science ®Google Scholar
• Ouzaid I, Capitanio U, Staehler M, et al. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol. 2019;2(2):141–149.
   PubMed Web of Science ®Google Scholar
• Husillos AA, Carbonero GM, Gonzalez EC. Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma? World J Nephrol. 2015;4(2):254–262.
   PubMedGoogle Scholar
• Procopio G, Apollonio G, Cognetti F, et al. Sorafenib versus observation following radical metastasectomy for clear-cell renal cell carcinoma: results from the phase 2 randomized open-label RESORT study. Eur Urol Oncol. 2019;2(6):699–707.
   PubMed Web of Science ®Google Scholar
• Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551–561.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2018. Available from: https://www.r-project.org/index.html
   Google Scholar
• Fergusson D, Aaron SD, Guyatt G, et al. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ. 2002;325(7365):652–654.
   PubMed Web of Science ®Google Scholar
• Appleman LJ, Puligandla M, Pal SK, et al. Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: a trial of the ECOG-ACRIN cancer research group (E2810). J Clin Oncol. 2019;37(15):4502.
   Web of Science ®Google Scholar
• Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16(6):2261–2266.
   PubMed Web of Science ®Google Scholar
• Zaid HB, Parker WP, Safdar NS, et al. Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. J Urol. 2017;197(1):44–49.
   PubMed Web of Science ®Google Scholar
• Alt AL, Boorjian SA, Lohse CM, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117(13):2873–2882.
   PubMed Web of Science ®Google Scholar
• Tosco L, Van Poppel H, Frea B, et al. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur Urol. 2013;63(4):646–652.
   PubMed Web of Science ®Google Scholar
• Verbiest A, Couchy G, Job S, et al. Molecular subtypes of clear-cell renal cell carcinoma are prognostic for outcome after complete metastasectomy. Eur Urol. 2018;74(4):474–480.
   PubMed Web of Science ®Google Scholar
• Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer. 2010;1(2):152–163.
   PubMedGoogle Scholar
• Beuselinck B, Verbiest A, Couchy G, et al. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. Acta Oncol. 2018;57(4):498–508.
   PubMed Web of Science ®Google Scholar
• Kothari G, Foroudi F, Gill S, et al. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 2015;54(2):148–157.
   PubMed Web of Science ®Google Scholar
• Franzese C, Franceschini D, Di Brina L, et al. Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma. J Urol. 2019;201(1):70–76.
   Web of Science ®Google Scholar
• Bang HJ, Littrup PJ, Goodrich DJ, et al. Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation. J Vasc Interv Radiol. 2012;23(6):770–777.
   PubMed Web of Science ®Google Scholar
• Gardner CS, Ensor JE, Ahrar K, et al. Cryoablation of bone metastases from renal cell carcinoma for local tumor control. J Bone Joint Surg Am. 2017;99(22):1916–1926.
   PubMed Web of Science ®Google Scholar
• Stenman M, Sinclair G, Paavola P, et al. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005–2014. Radiother Oncol. 2018;127(3):501–506.
   PubMed Web of Science ®Google Scholar